Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature.

Abstract

Data regarding ceftaroline use for meticillin-resistant Staphylococcus aureus bacteraemia (MRSAB) are lacking. Here we review the outcomes of 31 patients with MRSAB treated with ceftaroline, including 9 patients with endocarditis. Clinical success was observed in 23 patients (74.2%). Adverse events associated with prolonged therapy were rare and included eosinophilic pneumonia, rash and diarrhoea. We conclude that ceftaroline can be used for MRSAB.

• Authors: Hari M Polenakovik, Craig M Pleiman
• Journal: International journal of antimicrobial agents (Int J Antimicrob Agents) Vol. 42 Issue 5 Pg. 450-5 (Nov 2013) ISSN: 1872-7913 [Electronic] Netherlands
• PMID: 23993067 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Chemical References

• Anti-Bacterial Agents
• Cephalosporins
• T 91825

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anti-Bacterial Agents (therapeutic use)
• Bacteremia (drug therapy, microbiology)
• Cephalosporins (therapeutic use)
• Drug-Related Side Effects and Adverse Reactions (epidemiology, pathology)
• Female
• Humans
• Male
• Methicillin-Resistant Staphylococcus aureus (isolation & purification)
• Middle Aged
• Staphylococcal Infections (drug therapy, microbiology)
• Treatment Outcome
• Young Adult